Karin Sundfeldt

Sahlgrenska University Hospital — Sweden

Medicine · Health Sciences

37h-index4.0kcitations223works0.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(138), PARP inhibition in cancer therapy(31), Endometrial and Cervical Cancer Treatments(17), Endometriosis Research and Treatment(16), Virus-based gene therapy research(14)

Publications198 total

Detecting <scp> <i>TP53</i> </scp> mutations in paired liquid and tissue biopsies from patients with high‐grade serous ovarian carcinoma
International Journal of Cancer·2025Open Access
Full-length multiplexed 16S rRNA gene sequencing works well in self-collected decade old cervicovaginal fluid on paper cards
2025Open Access
Deep plasma proteomics identifies and validates an eight-protein biomarker panel that separate benign from malignant tumors in ovarian cancer
Communications Medicine·2025· 4 citedOpen Access
Novel glycovariant biomarkers of CA125 and CA15-3 and their diagnostic performance across histotypes of ovarian cancer: A multi-cohort study in Sweden and Finland
European Journal of Obstetrics & Gynecology and Reproductive Biology·2025Open Access
Ovarian cancer risk and survival according to tumor sex hormone receptor expression: An ovarian Cancer association consortium and ovarian tumor tissue analysis consortium pooled analysis
Gynecologic Oncology·2025· 2 citedOpen Access
Letter to the editor: <scp>FIGO</scp> Position statement on opportunistic salpingectomy as an ovarian cancer prevention strategy
International Journal of Gynecology & Obstetrics·2025
Plasma And Tumor Levels Of Leucine-Rich Repeats And Immunoglobulin-Like Domains Protein 1 (LRIG1) Are Associated With Survival In Ovarian Carcinoma
International Journal of Gynecological Cancer·2025
MUC1 and glycan probing of CA19-9 captured biomarkers from cyst fluids and serum provides enhanced recognition of ovarian cancer
Scientific Reports·2025· 2 citedOpen Access
Optimization of Pre-Analytical Handling to Maintain DNA Integrity in Diagnostic Papanicolaou Tests
Journal of Molecular Diagnostics·2025· 2 citedOpen Access
Elevated Galectin-3 levels in the tumor microenvironment of ovarian cancer – implication of ROS mediated suppression of NK cell antitumor response via tumor-associated neutrophils
Frontiers in Immunology·2024· 4 citedOpen Access
Deep plasma proteomics identifies and validates an eight-protein biomarker panel that separate benign from malignant tumors in ovarian cancer
2024· 1 citedOpen Access
Supplementary Figure S10 from Concurrent RB1 Loss and &lt;i&gt;BRCA&lt;/i&gt; Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
2024Open Access
Supplementary Table S9 from Concurrent RB1 Loss and &lt;i&gt;BRCA&lt;/i&gt; Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
2024Open Access
Supplementary Figure S8 from Concurrent RB1 Loss and &lt;i&gt;BRCA&lt;/i&gt; Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
2024Open Access
Supplementary Figure S9 from Concurrent RB1 Loss and &lt;i&gt;BRCA&lt;/i&gt; Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
2024Open Access
Figure 1 from Concurrent RB1 Loss and &lt;i&gt;BRCA&lt;/i&gt; Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
2024Open Access
Supplementary Figure S6 from Concurrent RB1 Loss and &lt;i&gt;BRCA&lt;/i&gt; Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
2024Open Access
Supplementary Table S2 from Concurrent RB1 Loss and &lt;i&gt;BRCA&lt;/i&gt; Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
2024Open Access
Supplementary Table S20 from Concurrent RB1 Loss and &lt;i&gt;BRCA&lt;/i&gt; Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
2024Open Access
Supplementary Table S15 from Concurrent RB1 Loss and &lt;i&gt;BRCA&lt;/i&gt; Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
2024Open Access
page 1 of 10Next →

Frequent Co-authors

Björg Kristjánsdóttir(10), Lars O. Hedin(9), Mats Brännström(8), Karolina Partheen(6), Karin Ivarsson(5), Maria Lycke(5), Yihong Zhu(5), Constantina Mateoiu(5), Kristina Levan(5), Katarina Rask(4), Pernilla Dahm‐Kähler(4), Stefan Enroth(3), Karin Stålberg(3), Ulf Gyllensten(3), Mikael Nilsson(3), Per Olof Janson(3), P. O. Janson(3), Michael S. Anglesio(3), Ellen L. Goode(3), Catherine J. Kennedy(3)